Damien Roos-Weil - JoVE Visualize

Showing results (21-30 of 98) with videos related to

Pageof 10

Sort By:

Ejhaem|March 20, 2025

Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.

Blood Cancer Journal|March 15, 2020

Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged miceVeronique Della-Valle, Damien Roos-Weil, Laurianne Scourzic, et al.

Annals of Hematology|July 30, 2025

Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)Anne Quinquenel, Stéphane Leprêtre, Marie Sarah Dilhuydy, et al.

British Journal of Haematology|March 20, 2024

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)Kamel Laribi, Stéphanie Poulain, Lise Willems, et al.

Journal of Pharmaceutical and Biomedical Analysis|February 22, 2021

Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoringBenoit Llopis, Pascal Robidou, Nadine Tissot, et al.

Blood Advances|May 7, 2021

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Charles Herbaux, et al.

Journal of Cellular and Molecular Medicine|May 23, 2025

Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological CorrelationsElise Sourdeau, Clémentine Boccon-Gibod, Aurélien Corneau, et al.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 10, 2024

Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib-findings from three casesMarion Blaize, Guillaume Thizy, Alexandre Boissonnas, et al.

Leukemia|September 26, 2023

del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemiaLudovic Jondreville, Lea Dehgane, Cecile Doualle, et al.

American Journal of Hematology|August 31, 2021

Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impactDaphné Krzisch, Nayara Guedes, Clémentine Boccon-Gibod, et al.

Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:

Pageof 10

Ejhaem|March 20, 2025

Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.

Blood Cancer Journal|March 15, 2020

Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged miceVeronique Della-Valle, Damien Roos-Weil, Laurianne Scourzic, et al.

Annals of Hematology|July 30, 2025

Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)Anne Quinquenel, Stéphane Leprêtre, Marie Sarah Dilhuydy, et al.

British Journal of Haematology|March 20, 2024

Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)Kamel Laribi, Stéphanie Poulain, Lise Willems, et al.

Journal of Pharmaceutical and Biomedical Analysis|February 22, 2021

Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoringBenoit Llopis, Pascal Robidou, Nadine Tissot, et al.

Blood Advances|May 7, 2021

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Charles Herbaux, et al.

Journal of Cellular and Molecular Medicine|May 23, 2025

Phenotypic Profile of Waldenström Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological CorrelationsElise Sourdeau, Clémentine Boccon-Gibod, Aurélien Corneau, et al.

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 10, 2024

Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib-findings from three casesMarion Blaize, Guillaume Thizy, Alexandre Boissonnas, et al.

Leukemia|September 26, 2023

del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemiaLudovic Jondreville, Lea Dehgane, Cecile Doualle, et al.

American Journal of Hematology|August 31, 2021

Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impactDaphné Krzisch, Nayara Guedes, Clémentine Boccon-Gibod, et al.

Pageof 10